Circulating levels of carboxy-methyl-lysine (CML) are associated with hip fracture risk: The cardiovascular health study

Journal of Bone and Mineral Research

Volumn 29, Issue 5, 2014, Pages 1061-1066

  Barzilay, Joshua I ^a   Bůžková, Petra ^b   Zieman, Susan J ^c   Kizer, Jorge R ^d   Djoussé, Luc ^e   Ix, Joachim H ^f   Tracy, Russell P ^g   Siscovick, David S ^b   Cauley, Jane A ^h   Mukamal, Kenneth J ⁱ  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

bone mineral density; bone quality; carboxy methyl lysine; cardiovascular health study; hip fracture risk

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CYSTATIN C; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BONE DENSITY; ENERGY EXPENDITURE; FEMALE; GENDER; GLOMERULUS FILTRATION; HIP FRACTURE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SMOKING; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; FOLLOW UP; HIP FRACTURES; MULTICENTER STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HIP FRACTURES; HUMANS; INCIDENCE; LYSINE; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899109327     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2123     Document Type: Article

References (24)

1. Wang X, Shen X, Li X, Agrawal CM,. Age-related changes in the collagen network and toughness of bone. Bone. 2002; 31: 1-7.
2. Saito M, Marumo K,. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010; 2: 195-214.
3. Yamagishi S-I,. Role of advanced glycation end products (AGE) in osteoporosis in diabetes. Curr Drug Targets. 2011; 11: 2096-102.
4. Reddy S, Bichler J, Wells Knecht KJ, Thorpe SR, Baynes JW,. N-epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995; 34: 10872-8.
5. Vashisth D,. Advanced glycation end products and bone fracture. IBMS Bonekey. 2009; 6: 268-78.
6. Gineyts E, Munoz F, Bertholon C, Sornay-Rendu E, Chapurlat R,. Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos Int. 2010; 21: 243-50.
7. Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T,. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008; 26: 93-100.
8. Tanaka S, Kuroda T, Saito M, Shiraki M,. Urinary pentosidine improves risk classification using fracture risk assessment. J Bone Miner Res. 2011; 26: 2778-84.
9. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T,. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 1013-9.
10. Schwartz AV, Garnero P, Hillier TA, et al.; Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94: 2380-6.
11. Hein G, Wiegand R, Lohmann G, Stein G, Franke S,. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysineare elevated in serum of patients with osteoporosis. Rheumatology (Oxford). 2003; 42: 1242-6.
12. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1: 263-76.
13. Cushman M, Cornell ES, Howard PR, Boville EG, Tracy RP,. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995; 41: 264-70.
14. Barzilay JI, Blaum C, Moore T, et al. Insulin resistance and inflammation as precursors of frailty: The Cardiovascular Health Study. Arch Intern Med. 2007; 167: 635-41.
15. Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of N-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004; 47: 1376-9.
16. Zhang X, Frischmann M, Kientsch-Engel R, et al. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med. 2005; 43: 503-11.
17. Wilcox R,. Trimming and Winsorization. Encyclopedia of biostatistics. Hoboken, HJ: Wiley Online Library; 2005.
18. R Foundation for Statistical Computing. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing [updated 2013 Sep 25; cited 2013 Dec 14]. Available from: http://www.R-project.org.
19. Viguet-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006; 39: 1073-9.
20. Saito M, Fujii K, Soshi S, Tanaka T,. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006; 17: 986-95.
21. Karim L, Tang SY, Sroga GE, Vashishth D,. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int. 2013; 24: 2441-7.
22. Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD,. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol. 2008; 600: 140-7.
23. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007; 25: 577-83.
24. Zieman SJ, Kass DA,. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs. 2004; 64: 459-70.